The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia.
NCT ID: NCT00165711
Last Updated: 2019-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
INTERVENTIONAL
2003-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Can Oral Vitamin B12 and Folate Supplementation Preserve Cognitive Function of Patients With Early Dementia?
NCT00164970
Do Iron And Vitamin B12 Injections Given Together, Improve Hemoglobin In Patients On Hemodialysis?
NCT04627181
Effect of Methylcobalamin and Cyanocobalamin Consumption on Vitamin B12 Nutritional Status
NCT05785585
A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type)
NCT07163364
VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study)
NCT00056225
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mecobalamin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Serum B12 \< 200 pmol/l
* Serum Homocysteine level \> 11.0 micro mol/L
Exclusion:
Significant communication problems
* deafness, dysarthria, dysphasia etc.
* unstable DM or hypertension
* alcohol abuse
* co-existing diseases which may affect cognition e.g. cognitive cardiac failure, respiratory failure
* folate \< 10 g/dl
* haemoglobin concentration \< 10g/d
* abnormal thyroid function test or VDRL
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Romeo Chu
Role: STUDY_DIRECTOR
Eisai Asia Regional Services Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chinese University of Hong Kong
Hong Kong, Hong Kong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AS-006 (MBL-HKG-05-01)
Identifier Type: -
Identifier Source: org_study_id
NCT00164983
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.